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The development of resistance to antimicrobials, which 
presents a major global public health threat has been 
evolving rapidly in recent years and spread almost all 
over the world (Codjoe & Donkor, 2017; Ventola, 2015). 
Globally, annual mortality rate due to antimicrobial 
resistance (AMR) is estimated at 700,000 and by the year 
2050 AMR is estimated to claim up to 10 million lives 
with an annual economic burden of US $100 trillion 
(Tadesse et al., 2017). In Africa, paucity of CRE data as 
presented in Figure 1 has hindered estimates of the 
magnitude of the problem, in addition to increased cases 
of treatment failure that has resulted in grave socio-
economic indices for the affected population (Kariuki & 
Dougan, 2014). 
 
Figure 1. Countries with CRE published research in Africa 
 
Carbapenems are generally regarded as the most 
effective type of antibiotics because of their proven effect 
against bacterial infections including those caused by 
antibiotic-resistant enterobacteriaceae (Iovleva & Doi, 
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2017). Unfortunately, resistance to carbapenems have 
been reported. The first case of carbapenem resistance 
was detected from Aeromonas hydrophila isolate in 1980s 
in Japan and subsequent cases were reported in London, 
UK (1982) from Serratia marcescens, California, USA (1984) 
and France (1990), both from Enterobacter cloacae (Codjoe 
& Donkor, 2017).  
Enterobacteriaceae, are a group of rod-like Gram-
negative bacteria, the most commonly encountered 
bacteria in clinical samples and may be responsible for 
approximately 80% of clinically significant Gram-
negative bacilli and 50% of all clinically significant 
bacteria (Perovic et al., 2016). In Africa, the problem is 
inflamed by suboptimal disease surveillance and 
healthcare system, ineffective infection control policies, 
indiscriminate use of antibiotics, poor diagnostic tools 
and lack of effective antibiotic stewardship programs in 
most parts of the continent (Manyi-Loh et al., 2018). In this 
review, we provide an up-to-date synthesis of CRE data 
in Africa, highlighting the need for more research within 
the continent on the surveillance of CRE genes. 
 
COMMUNITY AND HOSPITAL 
ACQUISITION OF CRE 
Infections due to CRE can be acquired in both clinical and 
community settings and are extremely difficult to treat. 
CRE, particularly Escherichia coli and Klebsiella pneumoniae, 
were relatively uncommon causes of hospital acquired 
infections until about two decades ago, and have since 
doubled in prevalence in recent years (Kelly et al., 2017). 
Isolation of patients helps reduce patient-to-patient 
transmission of CRE, and has led to a significant 
reduction of  CRE infections in patients with confirmed 
CRE colonisation at the time of admission, whether 
symptomatic or not (Magiorakos et al., 2017). The number 
of individuals that develop infection after colonisation 
remains unclear (Dortet et al., 2014). In a systematic 
review where 1,806 hospitalised patients identified as 
colonised with CRE at the time of admission were 
studied, only 299 (16.5%) were found to develop infection 
(Tischendorf et al., 2016). Evidence suggests that long-
term hospitalisation plays a critical role in the 
dissemination of CRE. Therefore, early detection of CRE 
in patients admitted to health facilities may help mitigate 
institutional outbreaks and halt regional spread of CRE 
(Codjoe & Donkor, 2017). 
The dissemination of CRE in the community is largely 
through carriage in commensal microflora, which might 
go undetected unless disease symptoms manifest 
(Kumarasamy et al., 2010). In poor communities with 
limited health facilities in Africa, even when symptoms 
develop, limited diagnostic and treatment options 
continues to promote dissemination of CRE among the 
population in affected communities (Maphumulo & 
Bhengu, 2019). 
The link between community and healthcare acquisition 
of  CRE has been previously described by Dortet et al. 
(2014) who reported that New Delhi metallobeta-
lactamase (NDM)-producing microorganisms isolated 
with high frequency in healthcare facilities and 
environmental niches disseminated into the community 
through patient transfer. Individuals who have a history 
of frequent exposure to CRE in a healthcare facility may 
easily spread CRE within the communities in Africa. 
Reports reveal that bacteria carrying the NDM enzyme 
may find its way outside the boundary of hospital 
settings into community water and sewage 
environments (Codjoe & Donkor, 2017). 
 
CARBAPENEMS 
Carbapenems differ from penicillins and cephalosporins 
in the chemical structure of their β-lactam ring (Hawkey 
& Livermore, 2012). Carbapenem refers to the 4:5 fused 
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ring lactam of penicillins with a double bond between C-
2 and C-3, but at C-1 position, sulphur is substituted with 
carbon (Papp-Wallace et al., 2011). The hydroxyethyl side 
chain of carbapenems is a radical departure from the 
regular structure of penicillins and cephalosporins, all of 
which have an acylamino substituent on the β-lactam 
ring; the stereochemistry of this hydroxyethyl side chain 
is a defining feature of carbapenems and is important for 
their high potency (Hawkey & Livermore, 2012). 
Additionally, this unique structure of carbapenems gives 
them protection against most β-lactamases such as 
metallo-β-lactamase (MBL) and ESBL, hence making 
them one of the last antibiotics of resort for treatment of 
antibiotic resistant infections (Codjoe & Donkor, 2017; 
Knapp & English, 2001). The carbapenems include 
imipenem, meropenem, doripenem, ertapenem, 
panipenem and biapenem. 
As β-lactam antibiotics, carbapenems have a penicillin-
like mode of action which kill bacteria by  inhibiting cell 
wall synthesis (Hawkey & Livermore, 2012). 
Carbapenems penetrate Gram-negative bacteria via 
outer membrane proteins (e.g. porins). The activity of 
carbapenems is initiated by penetrating the bacterial cell 
wall and binding to enzymes known as penicillin 
binding proteins (PBPs) through their active site (the β-
lactam ring). Carbapenems traverse the periplasmic 
space, where they acylate enzymes (transglycolases, 
transpeptidases, and carboxypeptidases) that catalyse 
bacterial cell wall (Peptidoglycan) synthesis (Codjoe & 
Donkor, 2017). Peptidoglycan synthesis involves 
simultaneous formation and autolysis, hence when 
formation is inhibited, autolysis continues leading to cell 
death. Carbapenems have a unique ability to bind 
multiple peptidoglycan synthesising enzymes (Hawkey 
& Livermore, 2012). Carbapenems also have a broad 
spectrum of activity and are indicated majorly for the 
treatment of serious conditions such as intra-abdominal 
infections, complicated urogenital infections and mixed 
bacterial infections that are resistant to other beta-lactam 
antibiotics (Zhanel et al., 2007). 
 
MOLECULAR EPIDEMIOLOGY OF CRE 
IN AFRICAN ISOLATES 
Carbapenem hydrolysing enzymes identified in 
enterobacteriaceae are classified into Ambler classes A 
(actively hydrolyse carbapenems and are partially 
inhibited by clavulanic acid), B (which are mainly in the 
class of β-lactamases with the ability to hydrolyse 
carbapenems but are susceptible to inhibition by EDTA 
and D (serine-β-lactamases which are poorly inhibited by 
EDTA or clavulanic acid) β-lactamases (Codjoe & 
Donkor, 2017). 
Globally, among enterobacteriaceae, blaNDM, blaVIM, 
and blaIMP are the most frequently identified 
carbapenem resistant genes (Sekyere et al., 2016). In the 
United States and South America, Class A 
carbapenemases like K. pneumoniae carbapenemases 
(KPC) and Guiana extended spectrum (GES) are the 
most prevalent CRE genes, whereas in Europe 
substantial cases of KPC, including Imipenem-resistant 
Pseudomonas (IMP) and Verona integron-encoded 
metallo-β-lactamases (VIM) have been reported. Class D 
types of carabapenemases which consist of Oxacillin-
hydrolysing (OXA)-48-like enzymes in 
enterobacteriaceae and other OXA variants are 
commonly distributed in the Mediterranean. In India 
and Pakistan, Class B type especially NDM are prevalent 
(Codjoe & Donkor, 2017).  
In Africa, although the exact molecular epidemiology of 
carbapenemases and their genetic environment are not 
well studied, the blaOXA-48, blaIMP, blaVIM, and 
blaNDM in Acinetobacter baumannii, K. pneumoniae, 
Enterobacter cloacae, Citrobacter spp. and E. coli, 
Borneo Journal of Pharmacy, Vol 3 Issue 2, May 2020, Page 71 – 78  e-ISSN: 2621-4814 
74 
respectively are the dominating carbapenemase genes 
characterised till date (Sekyere et al., 2016).  
In North Africa, carbapenem hydrolysing enzymes have 
been documented in countries such as Algeria, Tunisia, 
Morocco, Libya, and Egypt among enterobacteriaceae 
species. In Algeria, the first documented carbapenemase 
among enterobacteriaceae was VIM-19 enzyme in E. coli 
and K. pneumoniae (Rodriguez-Martinez et al., 2010). In 
Tunisia, Ktari et al. (2006) detected K. pneumoniae 
harbouring blaVIM-4 for the first time, which was co-
expressed with blaCTX-M-15 and blaCMY-4. Similarly, 
samples collected from patients of armed conflict from 
Libya and tested in Europe, were positive for blaOXA-48 
and blaOXA-23 in K. pneumoniae (ST101, ST147, ST383, 
and ECI). OXA-48 and NDM-1-producing 
enterobacteriaceae in  environmental, clinical and 
community settings have been reported to be prevalent 
in Morocco (Sekyere et al., 2016). Most class D 
carbapenemases (OXA-48 and blaOXA-48) were 
detected in Egypt from K. pneumoniae and E. coli in clinical 
specimens (Bathoorn et al., 2013). 
South Africa has published more articles on CRE than 
any other African country. Since 2012, the South African 
National Antimicrobial Resistance Reference Laboratory 
has reported a total of 1,618 carbapenem non-susceptible 
isolates from all specimen types. Of the 1,258 
enterobacteriaceae identified, 1,043 (83%) isolates were 
confirmed to have carbapenem resistant genes (Perovic et 
al., 2016). KPC-2 was first detected in South Africa in 2012 
(Brink et al., 2012) and is the most frequently reported in 
South Africa. Others such as blaOXA-48-like genes, have 
been found in K. pneumoniae, and in rare cases, E. coli and 
E. cloacae, where they mediate multidrug resistance. The 
first documented case of a blaNDM-1 in South Africa was 
in 2011 from a 63-year-old patient (Lowman et al., 2011). 
In the same year, the first blaKPC case in South Africa 
(blaKPC-2) reported from E. cloacae and K. pneumonia was 
also identified in K. pneumoniae (Brink et al., 2012). 
In West Africa, Nigeria and Ghana are the leading 
countries in the region that have documented CRE 
(Sekyere et al., 2016). In Nigeria, a study reported 
carbapenemase prevalence of 33.5% in a hospital setting 
Yusuf et al. (2012), and Chika et al. (2014) reported 12.5% 
and 15.4% carbapenemase production in E. coli and K. 
pneumoniae isolates. Molecular analysis of the genes 
responsible for resistance by Ogbolu & Webber (2014) 
identified blaNDM, blaVIM, and blaGES among P. 
aeruginosa, Proteus spp., K. pneumoniae, and E. coli, 
respectively as the genes responsible for resistance in β-
lactam antibiotic. Oladipo et al. (2018) reported a high rate 
of resistance to ertapenem (30%), levofloxacin (20%), and 
colistin sulphate (4%) in E. coli isolated from clinical 
specimens which they suggested could be as a result of 
plasmid transfer of AMR genes. 
In Ghana, a recent study involving 111 carbapenem 
resistant Gram-negative bacteria showed that none of the 
isolates harbour KPC genes. However, the 
carbapenemase genes identified were blaNDM-1, 
blaVIM-1, and blaOXA-48 in A. baumannii, Pseudomonas 
species, and K. pneumoniae respectively (Codjoe et al., 
2019). In Uganda, a study by Okoche et al. (2015) found 
carbapenemase prevalence of 22.4% and 28.6% using 
phenotypic and genotypic tests. In a recent study in the 
same country, among 56 isolates positive for 
carbapenemase encoding genes, K. pneumoniae was the 
species with the highest number (52.2%) and most 
prevalent genes were blaVIM (21,10.7%), blaOXA-48 (19, 
9.7%), blaIMP (12, 6.1%), blaKPC (10, 5.1%), and blaNDM-
1 (5, 2.6%). In Kenya, carbapenemase gene was first 
reported in a K. pneumoniae isolate (ST14) harbouring an 
blaNDM-1 on a 120 kbIncA/C plasmid in 2011 (Poirel et 
al., 2011). In Tanzania, in a study with 227 isolates, 21.6% 
were found to harbour IMP genes (Mushi et al., 2014). 
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Mushi et al. (2014) also documented blaIMP, blaVIM, 
blaOXA-48, and blaKPC in E. coli, K. pneumoniae, P. 
aeruginosa, and Salmonella in a collection of 80 out of 227 
isolates in a five-year prospective study between 2007 
and 2012. 
 
MECHANISM OF CARBAPENEM 
RESISTANCE AMONG 
ENTEROBACTERIACEAE 
Carbapenem resistance among members of  
enterobacteriaceae has been reported to be on the 
increase globally (Okoche et al., 2015). Mechanisms of 
carbapenems resistance include release of β-lactamases, 
efflux pumps, and mutations that interfere with the 
expression and/or function of porins and PBPs. 
Combinations of these mechanisms can cause high levels 
of carbapenem resistance in bacteria (Robin et al., 2010). 
While some bacterial strains may possess intrinsic 
resistance, some others may possess genetic elements 
such as plasmids or transposons which produce 
carbapenem-destroying β-lactamases (Kieffer et al., 2016). 
The acquired carbapenemases in the Ambler class A 
group which K. pneumoniae carbapenemases 
predominate, are the commonest type of β-lactamase 
enzymes encountered globally (Moussounda et al., 2017; 
Mitgang et al., 2018). Other carbapenem resistance 
mechanisms include hyper-expression of AmpC gene or 
decreased permeability of the outer membrane due to 
porin loss coupled with the expression of AmpC 
enzymes or ESBLs (Sangare et al., 2017). 
 
CRE SURVEILLANCE IN AFRICA 
The World Health Organization (WHO) 2014 report on 
global surveillance reported information on carbapenem 
resistance among Klebsiella from 7 of 47 WHO Africa 
region countries, and previous reviews of the 
epidemiology of CRE and underlying genotypes have 
yielded limited information on the WHO Africa region. 
Since its first detection, many countries particularly in 
Africa have limited or no surveillance activities that are 
specific for the threat posed by KPC. In fact, based on 
available published data, only South Africa has a national 
routine surveillance program in Africa; the National 
Health Laboratories/National Institute of 
Communicable Diseases through the Antimicrobial 
Resistance Reference Laboratories in the country screen 
isolates from various regions of the country suspected of 
carbapenemase production and publishes regularly in 
order to track the trends and the burden of carbapenem 
resistance in the country (Papp-Wallace et al., 2011). 
Laboratory personnel and facilities play a crucial role in 
identifying, mapping, quantifying and communicating 
AMR (Okeke, 2016). A number of techniques are in place 
for the detection of carbapenem-hydrolysing enzymes 
including, automated systems, disc diffusion, selective 
agar, modified Hodge test, synergy tests (such as E-tests 
or double disc tests), spectrometrics and molecular 
techniques (Codjoe & Donkor, 2017). The use of matrix-
assisted laser desorption ionisation time-of-flight mass 
spectrometry (MALDI-TOF MS) as a new method of 
detecting resistance in bacteria from fresh positive blood 
cultures has been described with good results (Muggeo 
et al., 2018). Carbapenem resistant enterobacteriaceae are 
detectable by the MALDI-TOF MS technique, and results 
can be obtained within 4 to 5 hours. MALDI-TOF MS is 
highly sensitive (97.1%), specific (98.9%) and can 
distinguish between carbapenemase-producing and 
non-carbapenemase-producing strains (Muggeo et al., 
2018). However, despite their high sensitivity and 
specificity, the deployment of these contemporary 
techniques in African settings has been limited by factors 
such as huge cost of equipment, consumables, reagents 
and lack of skilled personnel to operate the machines 
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among other factors (Barbarini  et al., 2015). Additionally, 
in most African countries, standardized diagnostic 
methods and antibiotic panels for screening ESBLs, 
including carbapenemases, are not yet established 
(Rawat & Najr, 2010). Hence, inadequate laboratory 
diagnosis and lack of surveillance suggests that CRE go 
undetected, untreated and might continue to spread 
unabated. In most cases, illnessess due to antibiotic 
resistant enteric bacteria are usually identified when 
treatment failure becomes recurrent (Okeke, 2016). 
 
CONCLUSION 
There is significant evidence to suggest that CRE is a 
major public health threat especially in Africa. Increasing 
carbapenem resistance and lack of more effective 
antibiotics beyond carbapenems suggests that a balance 
must be maintained between providing effective 
antibiotic treatment to patients who may die if not treated 
and preventing indiscriminate use of carbapenems. Due 
to epidemiological challenges such as variation in genetic 
makeup within and across countries, the detection and 
mitigation of the spread of carbapenem resistance 
amongst members of enterobacteriaceae has been 
challenging. With the paucity of data on CRE in Africa, 
studies using molecular techniques are urgently needed 
in the region. Ineffective detection methods which may 
lead to misdiagnosis and subsequent inappropriate 
antibiotic treatment, continues to promote the spread of 
CRE in hospital and community settings. Therefore, 
development of diagnostics that can detect AMR with 
high rapidity, sensitivity and specificity, at affordable 
prices is urgently needed in the developing world. In 
order to mitigate the impact of CRE, vaccines against 
enteric bacteria, new drug targets, prudent antimicrobial 
stewardship, and increased sensitization campaigns on 
appropriate use of antibiotics should be put in place 
across Africa. 
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